Review paper

Sulphonylureas in the management of type 2 diabetes: To be or not to be?

Volume: 1, Pages: 100002 - 100002
Published: Jan 1, 2021
Abstract
Sulphonylureas (SUs) for a long time occupied an essential role in the management of type 2 diabetes (T2D) as an alternative or a complement to metformin. However, the launch of new oral antidiabetic drugs (OADs), firstly DPP-4 inhibitors (gliptins) and more recently SGLT2 inhibitors (gliflozins), has markedly changed the scene. Indeed, in contrast to SUs, these new OADs (of course more expensive) offer the advantage of a very low risk of...
Paper Details
Title
Sulphonylureas in the management of type 2 diabetes: To be or not to be?
Published Date
Jan 1, 2021
Volume
1
Pages
100002 - 100002
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.